Table 1. Patient characteristics... | American Society of Hematology

Table 1.

Patient characteristics dichotomized by immunoglobulin free light chain (FLC)

	Percent of patients
Baseline characteristic	All	Baseline FLC < 152 mg/L	Baseline FLC ≥ 152 mg/L	P
Male	59	60	58	.79
Clonality, λ	74	75	72	.96
Prior therapy	36	43	29	.10
Kidney involvement	68	72	64	.40
Heart involvement	51	45	58	.17
Liver involvement	18	19	17	.97
Peripheral nerve involvement	17	18	15	.65
Autonomic nerve involvement	7	7	7	.98
Other organ involvement^*	27	21	43	.034
Reduced conditioning intensity†	24	15	32	.028
Year of PBSCT 1996-2002	41	43	39	.63

	Percent of patients
Baseline characteristic	All	Baseline FLC < 152 mg/L	Baseline FLC ≥ 152 mg/L	P
Male	59	60	58	.79
Clonality, λ	74	75	72	.96
Prior therapy	36	43	29	.10
Kidney involvement	68	72	64	.40
Heart involvement	51	45	58	.17
Liver involvement	18	19	17	.97
Peripheral nerve involvement	17	18	15	.65
Autonomic nerve involvement	7	7	7	.98
Other organ involvement^*	27	21	43	.034
Reduced conditioning intensity†	24	15	32	.028
Year of PBSCT 1996-2002	41	43	39	.63

There were 60 patients with baseline FLC below 152 mg/L and 59 with baseline FLC at or above 152 mg/L. FLC indicates involved immunoglobulin free light chain.

Other includes 15 patients microvascular (claudication); 17 patients gastrointestinal; 3 patients pulmonary; 2 patients myopathy; and 1 patient factor X deficiency with splenic rupture. Total does not add up to 35 because patients had more than one type of involvement

†

Melphalan 100 mg/m² to 140 mg/m² without total body irradiation

View Large

This Feature Is Available To Subscribers Only